Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial.
Journal: Annals of the rheumatic diseases
Published: March 19, 2024
Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.
Journal: Arthritis research & therapy
Published: February 07, 2024
Optimizing oral immune tolerance to Type II collagen in patients with rheumatoid arthritis: The importance of dose, interfering medication and genetics.
Journal: The American journal of the medical sciences
Published: January 19, 2024
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
Journal: Rheumatology and therapy
Published: November 28, 2023
Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: July 19, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
Journal: Rheumatology (Oxford, England)
Published: June 01, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.
Journal: Annals of the rheumatic diseases
Published: June 24, 2021
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
Journal: Rheumatology (Oxford, England)
Published: October 21, 2020
Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis.
Journal: Scandinavian journal of rheumatology
Published: February 21, 2018
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.
Journal: Rheumatology (Oxford, England)
Published: December 14, 2017
ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: October 13, 2017
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.
Journal: Rheumatology and therapy
Published: July 12, 2017
Last Updated: 09/26/2026